Pharvaris (NASDAQ:PHVS) Shares Gap Down – Should You Sell?

Pharvaris (NASDAQ:PHVS) gapped down prior to trading on Tuesday . The stock had previously closed at $18.74, but opened at $18.18. Pharvaris shares last traded at $17.89, with a volume of 36,789 shares changing hands.

Pharvaris Stock Down 2.0 %

The firm’s 50 day moving average is $19.18 and its two-hundred day moving average is $19.37.

Institutional Investors Weigh In On Pharvaris

Hedge funds have recently bought and sold shares of the company. Public Employees Retirement System of Ohio acquired a new position in Pharvaris in the 3rd quarter valued at about $57,000. Barclays PLC bought a new stake in shares of Pharvaris during the third quarter worth approximately $106,000. Geode Capital Management LLC grew its position in shares of Pharvaris by 18.4% in the third quarter. Geode Capital Management LLC now owns 36,977 shares of the company’s stock valued at $685,000 after purchasing an additional 5,753 shares during the last quarter. HighVista Strategies LLC increased its stake in shares of Pharvaris by 35.9% during the third quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after purchasing an additional 6,018 shares during the period. Finally, Jane Street Group LLC acquired a new stake in Pharvaris during the 3rd quarter worth approximately $526,000.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.